Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Others
    (5)
Filter
Search Result
Results for "

vkor

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    5
    TargetMol | Inhibitors_Agonists
Tecarfarin
ATI-5923, ATI-5000
T17025867257-26-9
Tecarfarin (ATI-5923) is an orally active, potent vitamin K epoxide reductase (VKOR) antagonist and cannabinoid-1 receptor inverse agonist with antithrombotic activity, which attenuates abdominal pain and increases intestinal transit in mice.
  • $149
In Stock
Size
QTY
Phenindione
Rectadione, Phenylindione, phenylindandione
T051483-12-5
Phenindione (Rectadione) is an indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Warfarin sodium
T0815L129-06-6
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
  • $30
In Stock
Size
QTY
Tecarfarin sodium
ATI-5923 sodium
T170241004551-83-0
Tecarfarin sodium is a novel orally active non-competitive vitamin K epoxide reductase antagonist. Tecarfarin sodium has the antithrombotic activity.
  • $1,670
8-10 weeks
Size
QTY
10-hydroxy warfarin
T3676983219-99-2
10-hydroxy Warfarin is a metabolite of (R)-warfarin .1It is formed from (R)-warfarin by the cytochrome P450 (CYP) isoform CYP3A4. 10-hydroxy Warfarin is an inhibitor of CYP2C9 (IC50= 1.6 μM), the enzyme that converts (S)-warfarin to its 6-hydroxy warfarin and 7-hydroxy warfarin metabolites.2 1.Kaminsky, L.S., and Zhang, Z.-Y.Human P450 metabolism of warfarinPharmacol. Ther.73(1)67-74(1997) 2.Jones, D.R., Kim, S.-Y., Guderyon, M., et al.Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarinChem. Res. Toxicol.23(5)939-945(2010)
  • $183
35 days
Size
QTY